Spravato vs Vanrafia
A plain-English comparison of two neurology drugs that may be accessible via NPP.
Side-by-side
| Spravato | Vanrafia | |
|---|---|---|
| Generic name | esketamine (CIII controlled substance) | atrasentan |
| Manufacturer | Janssen (Johnson & Johnson) | Novartis |
| Modality | Intranasal NMDA receptor antagonist (supervised in-office administration under REMS) | Oral selective endothelin A receptor antagonist (once-daily tablet) |
| Indication | Psychiatry (treatment-resistant depression) | Nephrology (IgA nephropathy) |
| FDA approval | March 5, 2019; monotherapy expansion January 2025 | April 2025 (accelerated) |
When physicians choose Spravato
Spravato is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Janssen (Johnson & Johnson) and represents an Intranasal NMDA receptor antagonist (supervised in-office administration under REMS) option in Psychiatry (treatment-resistant depression).
When physicians choose Vanrafia
Vanrafia is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by Novartis and represents an Oral selective endothelin A receptor antagonist (once-daily tablet) option in Nephrology (IgA nephropathy).
Both drugs - access via NPP
Both Spravato and Vanrafia can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).